Toward the Individualization of cytomegalovirus control after solid-organ transplantation: The importance of the "Individual Pathogenic Balance"

Clinical Infectious Diseases

Volumn 49, Issue 8, 2009, Pages 1167-1168

  Torre Cisneros, Julian ^a,b  

^a UNIVERSITY OF CÓRDOBA   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN B; IMMUNOSUPPRESSIVE AGENT; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL PRACTICE; CYTOMEGALOVIRUS INFECTION; DISEASE CONTROL; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; IMMUNOSUPPRESSIVE TREATMENT; NATURAL KILLER CELL; NONHUMAN; NOTE; ORGAN TRANSPLANTATION; PATHOGENESIS; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GENOTYPE; HUMANS; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; VIRULENCE;

EID: 70349923379     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/605634     Document Type: Note

References (8)

1. Manuel O, Åsberg A, Pang X, et al. Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solid-organ transplant recipients with cytomegalovirus disease. Clin Infect Dis 2009;49:1160-1166 (in this issue).
2. Crugh T, Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev 2009;22:76-98.
3. Cervera C, Lozano F, Saval N, et al. The influence of innate immunity gene receptors polymorphisms in renal transplant infections. Transplantation 2007; 83:1493-1500 (Pubitemid 46934073)
4. Manuel O, Pascual M, Trendelenburg M, Meylan PR. Association between mannose-binding lectin deficiency and cytomegalovirus infection after kidney transplantation. Transplantation 2007;83:359-362 (Pubitemid 46247871)
5. Goldfarb NS, Avery RK, Goormastic M, et al. Hypogammaglobulinemia in lung transplant recipients. Transplantation 2001;71:242-246
6. Emery VC, Sabin CA, Cope AV, Gor D, HassanWalker AF, Griffiths PD. Application of viralload kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000;355:2032-2036 (Pubitemid 30339241)
7. Åsberg A, Humar A, Rollag H, et al; VICTOR Study Group. Oral valgancidovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007; 7: 2106-2113 (Pubitemid 47247057)
8. Manuel O, Pang XL, Humar A, Kumar D, Doucette K, Preiksaitis JK. An assessment of donorto-recipient transmission patterns of human cytomegalovirus by analysis of viral genomic variants. J Infect Dis 2009;199:1621-1628